StockNASDAQ · US · USDHealthcare · Drug Manufacturers - Specialty & Generic
$CPIX
CUMBERLAND PHARMACEUTICALS INC
Cumberland Pharmaceuticals is a specialty pharmaceutical company that acquires, develops and commercializes branded prescription drugs for hospital acute care, gastroenterology and oncology markets. Its U.S. portfolio includes Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ and Talicia, used to treat conditions including poisoning, pain and fever, constipation, chemotherapy-related nausea, hyponatremia, bacterial infections and H. pylori infection. Cumberland also develops ifetroban, a product candidate being evaluated in clinical studies, and its majority-owned subsidiary Cumberland Emerging Technologies works with academic research institutions on early-stage product candidates. Cumberland promotes its products through hospital, field and oncology sales divisions, and works with distribution and co-promotion partners. It sells products to wholesale pharmaceutical distributors in the United States and partners with companies in other countries to register and commercialize its medicines. It also earns income through product sales and international agreements that may include milestone payments, product supply payments and royalties. Cumberland is headquartered in Nashville, Tennessee.
Cumberland Pharmaceuticals reported 3Q 2026 revenue of $2.16M, up 1155% YoY, driven by transition services revenue. Net income was $77.78M, swinging to profit from a loss, with EPS at $5.07. The company completed a $100M Apotex transaction and is advancing its Ifetroban pipeline.
Cumberland Pharmaceuticals (CPIX) reported Q3 2026 results, highlighting a $100M strategic transaction and plans to submit an NDA for ifetroban to treat DMD-related cardiomyopathy. The company also announced positive top-line results from a systemic sclerosis trial. Cumberland's net income was $77.8M, with $80.6M in cash reserves. The company is focusing on developing new therapies for rare diseases.
Cumberland Pharmaceuticals (CPIX) will release Q3 2026 financial results and a company update on Nov. 10, 2026. A conference call will follow to discuss the results. The company focuses on developing treatments for rare diseases, with late-stage clinical trials for ifetroban in several conditions.
via TradingView
CPIX sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning CPIX (CUMBERLAND PHARMACEUTICALS INC). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent CPIX coverage spans financial news, earnings and regulation.
AlphAI scores every news story that mentions CPIX with an AI model for sentiment and relevance, and aggregates insider trades from CUMBERLAND PHARMACEUTICALS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Cumberland Pharmaceuticals reported 3Q 2026 revenue of $2.16M, up 1155% YoY, driven by transition services revenue. Net income was $77.78M, swinging to profit from a loss, with EPS at $5.07. The company completed a $100M Apotex transaction and is advancing its Ifetroban pipeline.
Cumberland Pharmaceuticals (CPIX) reported Q3 2026 results, highlighting a $100M strategic transaction and plans to submit an NDA for ifetroban to treat DMD-related cardiomyopathy. The company also announced positive top-line results from a systemic sclerosis trial. Cumberland's net income was $77.8M, with $80.6M in cash reserves. The company is focusing on developing new therapies for rare diseases.
Cumberland Pharmaceuticals (CPIX) will release Q3 2026 financial results and a company update on Nov. 10, 2026. A conference call will follow to discuss the results. The company focuses on developing treatments for rare diseases, with late-stage clinical trials for ifetroban in several conditions.
Cumberland Pharmaceuticals (CPIX) plans to seek FDA approval for ifetroban to treat DMD-related cardiomyopathy, using Phase 2 trial data and natural-history databases. The FDA granted a rolling review but raised concerns about evidence sufficiency. The Phase 2 trial showed a 5.4% improvement in left ventricular ejection fraction (p=0.002).
CUMBERLAND PHARMACEUTICALS INC (CPIX) filed an SEC Form 8-K — Other Events. Item 7.01 Regulation FD Disclosure. On October 26, 2026, Cumberland Pharmaceuticals Inc. (the “Company” or “Cumberland”), an innovation-focused biopharmaceutical company developing new products for rare diseases, issued a press release providing an update on its ifetroban product
CUMBERLAND PHARMACEUTICALS INC (CPIX) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events On October 23, 2026, Cumberland Pharmaceuticals Inc. (“Cumberland”) announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban for patients with systemic sclerosis. These results support the safety and tolerability of ifetroban
Cumberland Pharmaceuticals (CPIX) reported Phase 2a trial results for ifetroban in systemic sclerosis (SSc) patients. The drug was well-tolerated, with a safety profile consistent with prior studies. The trial was not designed to evaluate efficacy. Cumberland plans to submit results to the FDA and conduct further biomarker studies. SSc is a rare autoimmune disease with limited treatment options for cardiac manifestations.
Several biotech stocks hit 52-week highs on August 25, 2026. Generate Biomedicines (GENB) rose 15% to $22.67, despite a wider net loss. Biodesix (BDSX) climbed 10% to $30, reporting a 34% revenue increase. CareDx (CDNA) gained 6%, with Medicare coverage for its transplant tests. Cumberland Pharmaceuticals (CPIX) rose 10% to $8.70, advancing Ifetroban in trials. Cardiol Therapeutics (CRDL) increased 7% to $2.02, with CardiolRx in Phase 3 trials.
Biotech stocks hit 52-week highs Aug. 10 on trial and earnings updates. Silence Therapeutics (SLN) rose about 29% to $17.58 after Phase 2 SANRECO topline results for divesiran and a reduced Q2 net loss, plus an announced ~$150M ADS offering. AbCellera (ABCL) gained ~34% to $10.01 on Phase 2 ABCL635 data. Cumberland (CPIX) reached $8.45 on Phase 2 Ifetroban progress. Celldex (CLDX) rose to $43.21 on Barzolvolimab Phase 3/2 readouts. Biodesix (BDSX) hit $25.51 after Q2 revenue of $26.9M and FY gui
Cumberland Pharmaceuticals (Nasdaq: CPIX) reported Q2 2026 results and updated investors after closing a strategic transaction with Apotex Health. Apotex acquired Cumberland’s FDA-approved branded portfolio for $100 million plus $11 million for inventory and transition services. Cumberland declared a $1.50 special dividend. Q2 loss was $3.1 million from continuing operations and $4.1 million net. It reported $63 million assets and $4 million cash at June 30.